Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Biocon Pertuzumab Biosimilar CHMP Positive Opinion

Analysis based on 8 articles · First reported Sep 21, 2026 · Last updated Sep 22, 2026

Sentiment
15
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive CHMP opinion strengthens Biocon's biosimilar pipeline and positions it to capture share of the roughly $3.6 billion Pertuzumab market in Europe once International — European Commission approval is granted, a modest positive for Biocon shares. It also signals rising biosimilar competition that could pressure Roche's Perjeta franchise revenue over time, while broadening patient access and potentially lowering treatment costs for HER2-positive breast cancer in the European Union.

pharmaceuticals biotechnology healthcare

Biopharmaceutical, a wholly-owned subsidiary of Biocon, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Union — European Medicines Agency issued a positive opinion recommending marketing authorisation for its Pertuzumab biosimilar, branded Pebrilzo, a 420 mg concentrate solution for infusion for the treatment of HER2-positive breast cancer across multiple disease stages. The application was submitted by Biopharmaceutical Ireland Limited, an indirect wholly-owned subsidiary of Biopharmaceutical. The positive opinion is notable as the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA's tailored clinical development approach, which relies on advanced analytical and clinical pharmacology evidence to establish biosimilarity. The International — European Commission will now conduct the final review and issue its decision; until then the product is not authorised for use in the European Union. The reference biologic, Perjeta, marketed by Roche, reported total sales of over $3.6 billion in 2025. Biocon also recently secured a 10-year supply contract for the breast cancer therapy in Brazil under the country's Productive Development Partnership program. In India, several domestic players including Astec LifeSciences, Abbott Laboratories, Abbott Laboratories and Intas Pharmaceuticals market biosimilar alternatives of the drug.

50 Biocon secured 10-year supply contract Brazil
stock
Parent company of Biopharmaceutical and the primary beneficiary of the CHMP positive opinion, which advances its biosimilar portfolio in Europe and follows its Brazil supply contract.
Importance 95.0 Sentiment 45.0
govactor
Its CHMP issued the positive opinion recommending marketing authorisation, advancing the application to the International — European Commission for final decision.
Importance 70.0 Sentiment 5.0
govactor
Holds the final decision on granting marketing authorisation for Pebrilzo in the European Union; approval would enable commercial launch.
Importance 60.0 Sentiment 0.0
stock
Markets the reference biologic Perjeta, which recorded over $3.6 billion in 2025 sales; the biosimilar approval threatens future revenue erosion from European competition.
Importance 55.0 Sentiment -20.0
alliance
The target market where Pebrilzo would be authorised following International — European Commission approval, expanding patient access to HER2-positive breast cancer treatment.
Importance 40.0 Sentiment 5.0
cnt
Home market of Biocon and several competing biosimilar makers; the approval enhances India's position in global biosimilar exports.
Importance 25.0 Sentiment 5.0
cnt
Recently signed a 10-year supply contract with Biocon for the breast cancer therapy under its Productive Development Partnership program, complementing the European regulatory progress.
Importance 20.0 Sentiment 5.0
stock
One of several Indian domestic players marketing a Pertuzumab biosimilar alternative in India, facing increased competition from Biocon's European expansion.
Importance 15.0 Sentiment -5.0
stock
Indian pharmaceutical company marketing a Pertuzumab biosimilar alternative domestically, part of the competitive landscape noted in the articles.
Importance 15.0 Sentiment -5.0
priv
Indian pharmaceutical company mentioned among domestic marketers of Pertuzumab biosimilar alternatives in India.
Importance 10.0 Sentiment -5.0
Roche related ↔ European Union
European Union related ↔ India
European Union related ↔ Brazil
India related ↔ Brazil
Astec LifeSciences no relationship ↔ Abbott Laboratories Astec LifeSciences and Abbott Laboratories do not have a direct business-to-business relationship. Astec LifeSciences is
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.